BioCentury | Nov 26, 2018
Distillery Techniques


TECHNOLOGY: Gene profiling A Bayesian network-based method of analyzing non-silent mutations could help identify mutational interactions across different cancer types to predict patient outcomes and identify targets or new indications for drugs. The method involves...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Dec 19, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with p53 knocked out, ATRX knocked down and both PDGFRA and K27M-mutant H3.3A overexpressed could be useful for screening therapies to treat pediatric high-grade gliomas. In mice, embryos engineered in...
BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: TAF12 RNA polymerase II TATA box binding protein (TBP)-associated factor (TAF12); nuclear transcription factor Y γ (NFYC); RAD54-like (RAD54L)

...Cancer INDICATION: Brain cancer Mouse and patient sample studies suggest inhibiting TAF12 , NFYC or RAD54L...
...and RAD54L as drivers of CPC tumorigenesis. In primary CPC cells from mice, shRNA targeting RAD54L...
...the mouse model, orthotopic transplantation of CPC cells pretreated with shRNA against TAF12, NFYC or RAD54L...
BioCentury | Nov 18, 2010
Targets & Mechanisms

GABAA: better late

The vast majority of ischemic stroke patients are unable to receive treatment with tissue plasminogen activator (tPA) within the drug's three-hour efficacy window, and there are no approved therapies that promote recovery of motor function...
Items per page:
1 - 5 of 5